Promising new therapies have emerged for BRAF‐mutant melanoma patients, but NRAS‐mutant (NRASMut) melanoma, like other RAS‐driven tumors, continues to have poor prognosis and limited therapeutic options (Sullivan & Flaherty, 2013; Johnson et al, 2014; Posch et al, 2016; Vu & Aplin, 2016; Wong & Ribas, 2016). Here, NRAS is linked to melanoma.